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The identification of tyrosinase autoantibodies in some
patients with vitiligo has previously been reported. In
this study we have determined the B cell epitopes on
tyrosinase which are recognized by these auto-
antibodies. Deletion derivatives of tyrosinase cDNA
were constructed and then translated in vitro with the
concomitant incorporation of [35S]methionine into
the protein products. The 35S-labeled tyrosinase deriva-
tives were subsequently used in radioimmunoassays to
investigate the reactivity of sera from five vitiligo
patients. The epitope regions identified were: three in
a central region of tyrosinase (amino acids 240–255,
289–294, and 295–300) and two others towards the
C-terminal end of the protein (amino acids 435–447
Vitiligo is a common skin disorder characterized byareas of depigmentation resulting from loss of melano-cytes in the epidermis. Although the precise etiologyremains obscure, some studies have shown that anti-melanocyte antibodies are often present in the serum
of vitiligo patients (Naughton et al, 1983), and that there is a
correlation between the presence and level of these antibodies and
the extent (Naughton et al, 1986) and activity of vitiligo (Harning
et al, 1991). In addition, the serum from vitiligo patients can induce
damage to human melanocytes in vitro by antibody-dependent
cellular cytotoxicity (Norris et al, 1988). These findings suggest that
anti-melanocyte antibodies may be involved in disease pathogenesis,
although it is also possible that antibody production may merely
reflect a secondary immunologic response to melanocytes damaged
by other mechanisms.
Recent work has tried to identify the antigens against which
vitiligo antibodies react. Studies have shown that a number of
pigment cell antigens can be immunoprecipitated with vitiligo sera
(Cui et al, 1992). These antigens are located on the cell surface
with some being preferentially expressed on pigment cells and
others appearing to be common tissue antigens. Specifically, tyrosin-
ase (Song et al, 1994; Baharav et al, 1996; Kemp et al, 1997a),
tyrosinase-related protein (TRP)-2 (Kemp et al, 1997b; Okamoto
et al, 1998) and TRP-1 (Kemp et al, 1998) have been implicated
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and 461–479). Computer analysis of the potential B
cell epitopes on tyrosinase revealed that the epitope
regions recognized by the vitiligo sera were located in
areas predicted to be highly antigenic. In addition, the
centrally located antigenic regions (amino acids 289–
294 and 295–300) had amino acid sequence homology
to both tyrosinase-related protein-1 and 22. Thus, the
epitopes on tyrosinase recognized by vitiligo patient
sera are heterogeneous and include a region with
homology to two related proteins which may explain
the cross-reactivity previously noted between these
antigens. Key words: autoantigen/autoimmunity/epitope
mapping. J Invest Dermatol 113:267–271, 1999
as autoantigens in vitiligo, although in our studies antibodies to
these melanogenic enzymes were found at a low frequency (Kemp
et al, 1997a, b, 1998).
The aim of this study was to determine the B cell epitopes on
tyrosinase which are recognized by autoantibodies from patients
with vitiligo. We constructed deletion derivatives of tyrosinase
cDNA using either exonuclease III treatment (Putney et al, 1981;
Henikoff, 1984) or polymerase chain reaction (PCR) amplification.
Full-length tyrosinase cDNA and its deletion derivatives were then
translated in vitro to produce 35S-labeled intact and modified
proteins, respectively, which were subsequently used for testing
antibody reactivity.
MATERIALS AND METHODS
Patients Sera from five vitiligo patients were analyzed in this study
(one male, four females; mean age 50 y, range 24–64 y; disease duration,
3–22 y; vitiligo type: one segmental, one symmetrical/periorificial, three
symmetrical), which were previously shown to contain tyrosinase antibodies
(Kemp et al, 1997a). With respect to autoimmune disorders, the two
patients with the lowest levels of tyrosinase antibodies had no personal or
family history of associated autoimmune diseases. The three patients with
the highest levels of tyrosinase antibodies also had an associated autoimmune
disorder: Graves’ disease in one and autoimmune hypothyroidism in two.
All sera were kept frozen at –20°C. The study was approved by the Ethics
Committee of the Northern General Hospital, Sheffield, U.K. and all
subjects gave informed consent.
Generation of tyrosinase deletion derivatives by exonuclease III
treatment Deletion constructs of the expression plasmid pBSTYR
(Kemp et al, 1997a) were generated using a Nested Deletion Kit according
to the manufacturer’s instructions (Pharmacia, Uppsala, Sweden). Briefly,
plasmid DNA was digested with SacI restriction endonuclease (Promega,
Southampton, U.K.) residing in a 39 direction from the tyrosinase cDNA.
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Table I. Oligonucleotide primers used to generate tyrosinase cDNA fragments by PCRa
1–831 TYR1 (TTGAATTCGCCGCCATGCTCCTGGCTGTT) 1 TYR2 (AATCTAGACGCCTAGCTACAGACAATCTGCCA)
1–675 TYR1 1 TYR225 (AATCTAGACGCCTACAGCTTCTGGATTTCTTG)
1–717 TYR1 1 TYR240 (AATCTAGACGCCTACCGCCAGTCCCAATATGG)
1–765 TYR1 1 TYR255 (AATCTAGACGCCTACTGACCTCCCATGTACTC)
1–849 TYR1 1 TYR283 (AATCTAGACGCCTAGTTGTACTCCTCCAATCG)
1–867 TYR1 1 TYR289 (AATCTAGACGCCTAGCATAAAGACTGATGGCT)
1–885 TYR1 1 TYR295 (AATCTAGACGCCTATCCCTCGGGCGTTCCATT)
1–1305 TYR1 1 TYR435 (AATCTAGACGCCTAATTTCTGTACAGTGGTAT)
1–1344 TYR1 1 TYR448 (AATCTAGACGCCTAGTCATAGCCCAGATCTTT)
1–1383 TYR1 1 TYR461 (AATCTAGACGCCTATTGAAAAGAGTCTGGGTC)
aEcoRI and XbaI restriction sites are underlined.
Table II. Deletion derivatives used in determining the B cell epitopes on tyrosinase that are recognised by vitiligo sera
Tyrosinase construct Amino acids encodeda (bpb) Predicted molecular weight of Estimated molecular weight of
expressed proteinc (kDa) expressed proteind (kDa)
pcDNA3TYRe 1-529 (1-1587) 58 58
pTYR9.8 1-500 (1-1502) 55 56
pTYR9.10 1-480 (1-1441) 53 52
pTYR9.2 1-426 (1-1279) 47 47
pTYR10.7 1-398 (1-1194) 44 44
pTRY9.6 1-362 (1-1088) 40 42
pTYR9.1 1-354 (1-1063) 39 38
pTYR10.4 1-313 (1-940) 34 30
pTYR10.6 1-301 (1-903) 33 27
pTYR1.2 1-277 (1-831) 30 24
pTYR10.10 1-209 (1-632) 23 17
pTYR225 1-225 (1-675) 25 20
pTYR240 1-240 (1-717) 26 21
pTYR255 1-255 (1-765) 28 23
pTYR283 1-283 (1-849) 31 25
pTYR289 1-289 (1-867) 32 26
pTYR295 1-295 (1-885) 32 27
pTRY435 1-435 (1-1305) 48 45
pTYR448 1-448 (1-1344) 49 48
pTYR461 1-461 (1-1383) 51 50
aNumbers correspond to the amino acid residues of tyrosinase with the initiating methionine as residue one.
bNumbers correspond to base pairs of tyrosinase cDNA with the A residue of the initiating ATG codon assigned as base pair number one.
cPredicted from the amino acid sequence of the protein.
dEstimated from the mobility of the protein in SDS-polyacrylamide gels.
wEncodes full-length tyrosinase.
The plasmid was then digested with enzyme XbaI (Promega) upstream of
the SacI site, and exonuclease III was used to create unidirectional deletions
from the 39 end of the cDNA fragment (Putney et al, 1981; Henikoff,
1984). S1 nuclease treatment and ligation of the linear DNA were carried
out, and the recircularized plasmids were transformed into Escherichia coli
JM109 (Promega). Plasmid DNA was purified from individual transformants
using a Wizard Minipreps DNA Purification System (Promega) and
analyzed by agarose gel electrophoresis (Sambrook et al, 1989) to assess
which constructs still contained a fragment of tyrosinase cDNA. Appro-
priate plasmids were sequenced by the dideoxy termination method
according to a Sequenase Version 2.0 Kit (Amersham, Aylesbury, U.K.)
with [α-35S]dATP (NEN, Hounslow, U.K.) and M13 reverse primer
(Promega) in order to determine the exact location of the 39 end of the
tyrosinase cDNA fragment.
Subcloning of fragments of tyrosinase cDNA Tyrosinase cDNA
fragments of varying lengths were generated from tyrosinase cDNA in
pcDNA3TYR (Kemp et al, 1997b) by PCR amplification. Restriction
sites for EcoRI and XbaI were incorporated into the 59 and 39 oligonucleotide
primers, respectively, in order to allow subcloning of the PCR products
into pcDNA3 (Invitrogen, Abingdon, U.K.). The primers (Gibco-BRL,
Paisley, U.K.) used to generate the fragments are listed in Table I. The
numbers correspond to base pairs of tyrosinase cDNA with the A residue
of the initiating ATG codon assigned as base pair number one.
Samples of pcDNA3TYR DNA (50 ng) were subjected to 27 cycles of
PCR amplification in a DNA Thermal Cycler (Perkin-Elmer/Cetus,
Norwalk, CT) using the following conditions: 94°C, 1 min; 55°C, 1 min;
72°C, 2 min; and 72°C for 10 min to terminate the reaction. Reactions
were carried out in 50 µl volumes comprising 0.3 mM of each relevant
primer, 1 U of Expand High Fidelity PCR System (Boehringer Mannheim,
Lewes, U.K.), 0.1 mM deoxynucleotides dATP, dTTP, dCTP, and dGTP
(Pharmacia) in buffer containing 1.5 mM MgCl2, 10 mM Tris–HCl
(pH 8.3), 0.01% (wt/vol) gelatin, 50 mM KCl, 0.1% (vol/vol) Tween 20
and 0.1% (vol/vol) Nonidet p-40.
The PCR products were purified using a Wizard PCR Preps DNA
Purification System (Promega), restricted with EcoRI and XbaI, ligated
into pcDNA3 and then transformed into E. coli JM109. Plasmid DNA was
purified from individual transformants, analyzed by agarose gel electro-
phoresis and the appropriate recombinant plasmids were sequenced using
T7 and SP6 primers (Promega) to verify that no sequence errors had been
introduced.
In vitro translation and electrophoretic analysis The plasmid con-
structs were used in a TnT T7 coupled reticulocyte lysate system (Promega)
to produce and label tyrosinase and its deletion derivatives with [35S]me-
thionine in vitro as previously described (Kemp et al, 1997a). Sodium
dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis of in vitro translated
products was performed in 12.5% SDS–polyacrylamide resolving gels
(Sambrook et al, 1989; Kemp et al, 1997a), which were stained, dried, and
autoradiographed as described elsewhere (Sambrook et al, 1989; Kemp
et al, 1997a). Protein molecular weight standards have been detailed before
(Kemp et al, 1997a).
Immunoprecipitation Vitiligo sera were tested for binding to 35S-
tyrosinase and its labeled deletion derivatives in immunoprecipitation
experiments as detailed elsewhere (Kemp et al, 1997a). The reactivity of
each serum against each deletion derivative was assessed by the cpm
immunoprecipitated and then expressed as a percentage of binding relative
to full-length tyrosinase.
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Computer analysis Predictions of B cell epitopes were carried out as
previously described (Parker et al, 1986). GenBank homology searches
were performed using the Sequence Analysis Software package, GCG
(University of Wisconsin, WN).
RESULTS
In vitro translation of tyrosinase cDNA and its deletion
derivatives For identification of autoepitopes on tyrosinase, the
cDNA in pBSTYR was deleted with exonuclease III treatment.
As the deletions were carried out from the 39 end of the tyrosinase
cDNA, the correct translational reading frame was maintained.
DNA sequencing was used to determine the exact location of the
39 end of each of the tyrosinase cDNA deletion derivatives
(Table II).
PCR amplification was used to generate tyrosinase cDNA
fragments of varying lengths which were then cloned into pcDNA3
(Table II). DNA sequencing of the fragments was carried out to
verify that no sequence errors had been introduced.
Products generated from in vitro translation of tyrosinase cDNA
and its deletion derivatives were evaluated by SDS–polyacrylamide
gel electrophoresis and autoradiography (Fig 1a, b). Major bands
representing the intact and modified 35S-labeled tyrosinase proteins
were found in each case (Table II).
Immunoprecipitation of tyrosinase deletion derivatives with
sera from vitiligo patients Sera from five vitiligo patients were
tested for their ability to immunoprecipitate 35S-labeled tyrosinase
and its modified derivatives. The results of the reactivity of the
vitiligo sera with the tyrosinase deletion derivatives are summarized
in Table III.
When tyrosinase containing a C-terminal deletion of amino
acids 462–529 was used, the antibody binding of one patient serum
was reduced to 56% of the reactivity with full-length tyrosinase. A
C-terminal deletion of amino acids 436–529 caused a reduction of
tyrosinase antibody binding to 69%, in another serum studied.
Amino acid deletions 296–529, 290–529, and 241–529 caused a
decrease in binding relative to full-length tyrosinase of 35%, 36%,
and 33%, respectively, for three vitiligo sera.
These results indicate that multiple epitope domains exist on
tyrosinase: between amino acids 240 and 254 (DEAK-
CDICTDEYMGG), 289 and 294 (CNGTPE), and 295 and 300
(GPLRRN) located centrally in the tyrosinase molecule, and
between 435 and 447 (NGDFFISSKDLGYD) and 461 and 479
(QDYIKSYLEQASRIWSWLL) found towards the C-terminal of
the protein (Table IV).
The 39 end deletion procedure predominantly reveals those
antigenic regions which are closer to the N-terminus of the
polypeptide. We were therefore unable to confirm the reactivity
of three of the sera with the C-terminal antigenic regions because
of the presence of reactivity with epitope regions located nearer to
the N-terminal domain of tyrosinase.
Computer prediction of putative antigenic regions within
tyrosinase The computer prediction analysis identified several





QDSDPDSFQDYIKSYLEQ); and 500–529 (CRHKRKQLP-
EEKQPLLMEKEDYHSLYQSHL).
All the epitope regions defined by the vitiligo sera were found
in these putative antigenic areas: antigenic domains 289–294 and
295–300 were within the predicted epitope region 275–315,
antigenic domains 435–447 and 461–479 were located in the
predicted epitope region 430–470 and antigenic domain 240–254
was located in the predicted epitope region 230–260.
Comparison of identified epitope regions with the amino
acid sequences of TRP-1 and TRP-2 The amino acid
sequence of two of the identified epitope regions (amino acids
Figure 1. SDS–polyacrylamide gel electrophoresis and autoradio-
graphy of products arising from in vitro translation of tyrosinase
cDNA and its deletion derivatives. Tyrosinase cDNA and its deletion
derivatives were translated in vitro in a TnT T7 coupled reticulocyte lysate
system as described in Materials and Methods. Subsequently, 5 µl of the
reaction mixture were added to 20 µl of SDS sample buffer, boiled for
5 min and, 10 µl of this mixture were then analyzed by SDS–polyacrylamide
gel electrophoresis on a 12.5% gel. (a) Full-length tyrosinase in vitro
translated from pcDNA3TYR (lane 1); deletion derivatives of tyrosinase
in vitro translated from: pTYR9.8 (lane 2); pTYR9.10 (lane 3); pTYR9.2
(lane 4); pTYR10.7 (lane 5); pTYR9.6 (lane 6); pTYR9.1 (lane 7);
pTYR10.4 (lane 8); pTYR10.6 (lane 9); pTYR1.2 (lane 10); pTYR10.10
(lane 11). (b) pTYR461 (lane 1); pTYR448 (lane 2); pTYR435 (lane 3);
pTYR295 (lane 4); pTYR289 (lane 5); pTYR283 (lane 6); pTYR225 (lane
7); pTYR240 (lane 8); pTYR255 (lane 9).
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Table III. Reactivity of vitiligo sera to tyrosinase deletion
derivativesa
Patient
Tyrosinase construct 1 2 3 4 5
pcDNA3TYR 100 100 100 100 100
pTYR9.8 96 89 93 100 97
pTYR9.10 105 96 105 85 111
pTYR461 ndb nd nd 100 56
pTYR448 nd nd nd 102 53
pTYR435 nd nd nd 69 63
pTYR9.2 94 93 101 67 49
pTYR10.7 104 104 99 59 53
pTYR9.6 100 87 108 56 52
pTYR9.1 98 99 99 60 54
pTYR10.4 107 104 102 57 48
pTYR10.6 105 101 103 59 51
pTYR295 nd 92 35 nd nd
pTYR289 nd 36 36 nd nd
pTYR283 nd 40 39 nd nd
pTYR1.2 96 37 37 59 51
pTYR255 84 nd nd nd nd
pTYR240 33 nd nd nd nd
pTYR225 32 nd nd nd nd
pTYR10.10 33 35 37 61 49
aPercentage binding, relative to full-length tyrosinase, of each serum for each
construct is the mean of three experiments.
bnd, not determined.
Table IV. Epitope regions on tyrosinase recognised by
vitiligo seraa
Patient sera
1 2 3 4 5
Amino acids
240–254 1 – – – –
289–294 NA 1 – – –
295–300 NA NA 1 – –
435–447 NA NA NA 1 –
461–479 NA NA NA NA 1
aReactivities with epitope regions are indicated: 1, reactivity with the specified
epitope region; –, unreactive with the specified epitope region; NA, reactivity with
the specified epitope region unknown.
289–294 and 295–300) had homology to an amino acid sequence
in both TRP-1 (Kwon, 1993) and TRP-2 (Yokoyama et al, 1994):
a tyrosinase peptide of 12 residues (amino acids 291–302) included
eight identical and two conservatively changed amino acids when
compared with an amino acid sequence present in TRP-1 (amino
acids 305–318), and eight identical residues when compared with
an amino acid sequence in TRP-2 (amino acids 301–315). This is
illustrated in Fig 2.
DISCUSSION
The pathogenic role of anti-melanocyte antibodies, which are
frequently found in vitiligo patients (Naughton et al, 1983), remains
unclear and few autoantigens have been specifically identified.
Tyrosinase has been implicated as an autoantigen in vitiligo by a
number of studies (Song et al, 1994; Baharav et al, 1996; Kemp
et al, 1997a), although from our work autoantibodies to this enzyme
are present in relatively few patients: of 46 vitiligo sera tested in a
radioimmunoassay for tyrosinase antibodies, only five (11%) were
considered to be positive (Kemp et al, 1997a). Here we have
described the identification of B cell epitopes on tyrosinase which
are recognized by vitiligo sera containing tyrosinase autoantibodies.
The construction and expression of several deletion mutants of
tyrosinase enabled us to characterize multiple epitope domains:
between amino acids 240 and 254 (DEAKCDICTDEYMGG),
289 and 294 (CNGTPE), and 295 and 300 (GPLRRN) located
Figure 2. Amino acid sequence homology between an auto-
antigenic region of tyrosinase and a peptide sequence of TRP-1
and of TRP-2. Numbers represent the amino acid residues of the protein
with the initiation methionine being assigned as number one. Identical
amino acids are indicated by bold type-face and conservative amino acid
changes are underlined.
centrally in the tyrosinase molecule, and between 435 and 447
(NGDFFIS SKDLGYD) and 461 and 479 (QDYIKSYLEQAS-
RIWSWLL) found towards the C-terminal of the protein. Because
the 39 deletion method predominantly reveals those antigenic
regions which are closer to the N-terminus of the polypeptide,
we could not confirm the reactivity of three of the sera with the
C-terminal antigenic regions because of the presence of reactivity
with epitope regions located nearer to the N-terminus of
tyrosinase. In order to examine the reactivity of these sera with
the C-terminus of tyrosinase, further deletion derivatives would
need to be constructed which exclude the central regions of
the protein.
B cell epitopes predicted by computer analysis, indicated five
main antigenic regions on tyrosinase. All the epitope regions
defined by the vitiligo sera were found in these putative antigenic
areas: antigenic domains 289–294 and 295–300 were within the
predicted epitope region 275–315, antigenic domains 435–447 and
461–479 were located in the predicted epitope region 430–470
and antigenic domain 240–254 was located in the predicted epitope
region 230–260.
As tyrosinase shows amino acid sequence homology with TRP-
1 (Kwon, 1993) and TRP-2 (Yokoyama et al, 1994), the identified
tyrosinase autoantigenic regions were compared for amino acid
homology with both the tyrosinase-related enzymes to locate
possible cross-reactive domains. The amino acid sequence of two
of the identified epitope regions (amino acids 289–294 and 295–
300) had homology to an amino acid sequence in both TRP-1
(Kwon, 1993) and TRP-2 (Yokoyama et al, 1994): a tyrosinase
peptide of 12 residues (amino acids 291–302) included eight
identical and two conservatively changed amino acids when com-
pared with an amino acid sequence present in TRP-1 (amino acids
305–318), and eight identical residues when compared with an
amino acid sequence in TRP-2 (amino acids 301–315). This
finding is consistent with our previous studies in which we identified
three vitiligo patients whose sera contained tyrosinase antibodies
which cross-reacted with both TRP-1 and TRP-2 (Kemp et al,
1997a,b, 1998). In this work, two of these patients had tyrosinase
antibodies which reacted with epitope regions 289–294 and 295–
300, respectively. The third patient had tyrosinase antibodies which
recognized the 240–254 antigenic domain. Reactivity of this patient
sera with the 289–294 and 295–300 epitope regions, however,
may have been masked by antibody binding to the site closer to
the N-terminus of tyrosinase. The sera from the remaining two
patients, which were found to contain tyrosinase antibodies but
not antibodies to TRP-2 or TRP-1 (Kemp et al, 1997a, b, 1998),
reacted with epitopes 435–447 and 461–479, respectively, which
did not appear to be homologous to amino acid sequences in either
TRP-1 or TRP-2.
These results indicate that multiple regions of tyrosinase are
epitopes for autoantibodies from the vitiligo patients studied and
regions 289–294 and 295–300 are likely to contain epitopes which
VOL. 113, NO. 2 AUGUST 1999 MAPPING OF TYROSINASE AUTOANTIBODIES 271
are cross-reactive with both TRP-1 and TRP-2. It is possible that
if we were able to test a larger number of vitiligo patient sera
containing tyrosinase antibodies, more autoreactive epitopes may
be identified. In addition, a drawback of using deletion derivatives
in the mapping of B cell epitopes is that the identification of
discontinuous epitopes is excluded.
At present we do not know if the tyrosinase autoantibodies
found in these patients have a role in the development of their
vitiligo. Tyrosinase antibodies, however, occur at a low frequency
in vitiligo sera and the enzyme does not therefore appear to be a
major antigen in patients with this disorder. Given the high
incidence of anti-melanocyte antibodies in vitiligo sera (Naughton
et al, 1983), it seems likely that melanocyte autoantigens other
than tyrosinase are important targets of the autoimmune response
in vitiligo.
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